Hycult Biotech is a biotechnology startup with a slogan "Bringing innate immunity to the next level." Established in 1994, the company specializes in manufacturing research reagents in the field of innate immunity, focusing on antimicrobial peptides, complement, acute phase proteins, LPS, microbial toxins, inflammation, and cell- and tissue damage. Hycult Biotech collaborates with researchers globally to develop innovative research solutions that contribute to better treatment, monitoring, and prevention of diseases.
The company operates in the biotechnology, health care, and manufacturing industries, emphasizing the translation of scientific insights into practical applications. Hycult Biotech's products, including assays, antibodies, and proteins, are co-developed with the aim of enhancing disease understanding and offering improved research and diagnostic tools.
As of now, there is no public information available regarding the company's recent investments or investors, signaling a potential opportunity for venture capital firms to explore collaboration or funding possibilities with Hycult Biotech.
There is no investment information
No recent news or press coverage available for Hycult Biotech.